ArticleFrontiers in cardiovascular medicine2025
Tanyu Tongzhi Formula relieves the progression of atherosclerotic plaque through lipid regulation and anti-inflammatory effects.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Tanyu Tongzhi Formula (TTF), a clinically proven empirical prescription, has been utilized to treat atherosclerosis (AS) for decades. This study aimed to investigate the therapeutic mechanisms of TTF against AS by integrating bioinformatics, multi-omics, and experimental validation. Methods: The metabolites of TTF in serum were identified using Ultra Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS). Bioinformatics was employed to predict drug targets and mechanisms of action. ApoE Results: Bioinformatics identified 28 key targets of TTF in AS treatment, primarily associated with inflammation and lipid metabolism. TTF significantly reduced aortic plaque area, attenuated hepatic steatosis, and enhanced plaque collagen content. It decreased the serum levels of lipids and pro-inflammatory mediators (IL-6 and IL-1β) in AS mice. Sphingolipids are the most significantly different lipids. In LPS-stimulated PMs, TTF suppressed IL-6 mRNA and NLRP3 inflammasome activation while upregulating IL-10 mRNA. Conclusions: TTF exerts its anti-atherosclerotic effect through inflammation reduction. These findings provide a scientific basis for its clinical application in AS treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.